ArticleThoracic cancer2024

Benefits of camrelizumab plus carboplatin and albumin paclitaxel as induction therapy for locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma.

Li Chao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.